IL1B and Cognitive impairment: These two neflamapimod dose levels in this vehicle were selected because their twice daily administration for three weeks was previously demonstrated to be pharmacologically active in aged rats with cognitive deficits attributed to chronic inflammation-induced, IL-1β-mediated impairment of synaptic plasticity [45].